This multicenter phase I/II study investigated the maximum tolerated dose ( @entity21035 ), safety, and efficacy of low dose intravenous (IV) @entity3601 in combination with @entity1749 for @entity1 with relapsed @entity1582 ( @entity1582 ). @entity1 received @entity1749 1.3 mg/m(2) on days 1, 4, 8, and 11 and escalating doses of IV @entity3601 (2.5-10.0 mg/m(2)) on day 2 of a 28-day cycle for a maximum of eight cycles. @entity619 20 mg was added for progressive or stable disease. Fifty-three @entity1 were enrolled. The @entity21035 was defined at @entity3601 7.5 mg/m(2) and @entity1749 1.3 mg/m(2). The overall response rate (ORR) was 68% (23% complete or near-complete responses [ @entity14078 ]) whilst at the @entity21035 (n = 33) the ORR was 76% (34% @entity14078 ). After median follow-up of 17 months, the median progression free survival was 10 months, rising to 12 months at the @entity21035 (P < 0.05 vs. non- @entity21035 regimens). The median overall survival was 28 months, but was not yet reached at the @entity21035 . Grade 3/4 adverse events included @entity882 (62%), @entity1398 (57%), @entity281 (21%), and @entity16 (15%). @entity1749 and low-dose IV @entity3601 combination therapy is a safe and highly effective regimen for @entity1 with relapsed @entity1582 . These data suggest further investigation of this combination is warranted.

@entity1749 , low-dose intravenous @entity3601 , and @entity619 for XXXX with relapsed @entity1582 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity21035 :: ('4493', 'Gene') :: ['MTD'] @entity14078 :: ('4827', 'Gene') :: ['CR/nCR'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy'] @entity3601 :: ('MESH:D008558', 'Chemical') :: ['melphalan'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'MM'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['Dexamethasone'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity1749 :: ('MESH:C400082', 'Chemical') :: ['bortezomib', 'Bortezomib']
@entity1 :: (9606,Species) :: ['patients']
